A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer

被引：0
|
作者：
Hurwitz, H [1 ]
Fernando, N [1 ]
Yu, DH [1 ]
Morse, M [1 ]
Blobe, G [1 ]
Gockerman, J [1 ]
Odogwu, L [1 ]
Mahon, M [1 ]
Truax, R [1 ]
Franklin, A [1 ]
机构：
[1] Duke Univ, Durham, NC USA
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：285 / 285
页数：1
相关论文
共 50 条
  • [21] Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer
    Borner, MM
    Dietrich, D
    Stupp, R
    Moran, R
    Honegger, H
    Wernli, M
    Herrmann, R
    Pestalozzi, BC
    Saletti, P
    Hanselmann, S
    Müller, S
    Brauchli, P
    Castiglione-Gertsch, M
    Goldhirsch, A
    Roth, AD
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) : 1759 - 1766
  • [22] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
    Cabebe, Elwyn C.
    Fisher, George A.
    Sikic, Branimir I.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1082 - 1087
  • [23] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
    Elwyn C. Cabebe
    George A. Fisher
    Branimir I. Sikic
    Investigational New Drugs, 2012, 30 : 1082 - 1087
  • [24] Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer
    Petrioli, Roberto
    Francini, Edoardo
    Cherri, Sara
    Torre, Pamela
    Fiaschi, Anna Ida
    Miano, Salvatora Tindara
    Marrelli, Daniele
    Rovello, Franco
    Francini, Guido
    CLINICAL COLORECTAL CANCER, 2018, 17 (04) : E663 - E669
  • [25] Phase II study of bevacizumab in combination with capecitabine as first line treatment in elderly patients with metastatic colorectal cancer (MCC)
    Vrdoljak, E.
    Omrcen, T.
    Hrabar, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer
    Vrdoljak, Eduard
    Omrcen, Tomislav
    Boban, Marijo
    Hrabar, Andina
    ANTI-CANCER DRUGS, 2011, 22 (02) : 191 - 197
  • [27] Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
    Yu Hong Li
    Hui Yan Luo
    Feng Hua Wang
    Zhi Qiang Wang
    Miao Zhen Qiu
    Yan Xia Shi
    Xiao Juan Xiang
    Xiao Qing Chen
    You Jian He
    Rui Hua Xu
    Journal of Cancer Research and Clinical Oncology, 2010, 136 : 503 - 510
  • [28] Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
    Li, Yu Hong
    Luo, Hui Yan
    Wang, Feng Hua
    Wang, Zhi Qiang
    Qiu, Miao Zhen
    Shi, Yan Xia
    Xiang, Xiao Juan
    Chen, Xiao Qing
    He, You Jian
    Xu, Rui Hua
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (04) : 503 - 510
  • [29] Clinical Efficacy of Bevacizumab in Conjunction with Oxaliplatin and Capecitabine in Managing Metastatic Colorectal Cancer
    Zang, J.
    Zhang, X.
    Wang, Qing
    Gan, Jianchen
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 85 : 290 - 294
  • [30] Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC).
    Meyerhardt, JA
    Xhu, A
    Enzinger, PC
    Ryan, DP
    Clark, JW
    Kulke, MH
    Michelini, A
    Vincitore, M
    Thomas, A
    Fuchs, CS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 265S - 265S
12345